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The P670 promoter of HPV16 directs transcription of the virus late genes in the differentiating epithelium. We found that CCAAT/enhancer
binding protein h (C/EBPh), a key transcription factor that induces the terminal differentiation of keratinocytes, enhanced the P670-driven
transcription in transient reporter assays in HeLa cells and human primary keratinocytes, whereas it inhibited, as reported previously, the
transcription from the early P97 promoter. An electrophoretic mobility shift analysis identified two binding sites in the upstream region of P670 for
a bacterially expressed C/EBPh. A chromatin immunoprecipitation analysis demonstrated that C/EBPh bound to these sites of the P670 reporter
plasmid in HeLa cells. Nucleotide substitutions in these sites in the reporter plasmid abrogated the enhancement by C/EBPh in the transient HeLa
and keratinocyte assays, indicating that the C/EBPh-binding to these sites is required for the enhancement of transcription from P670. These results
suggest that C/EBPh is involved in enhancing transcription from the P670 during keratinocyte differentiation.
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Human papillomaviruses (HPVs), small icosahedral viruses
with circular double-stranded DNA genomes of 8 k base pairs
(bp), cause proliferative lesions of the skin or mucosa (zur
Hausen, 1996). To date more than 100 genotypes of HPVs
have been identified and classified based on the homology of
genomic DNA. HPVs that infect the genital epithelia are
divided into two groups: low-risk types such as HPV type 6
(HPV6) and HPV11 found mainly in benign condyloma and
high-risk types such as HPV16, HPV18, HPV31, and HPV33
found in cervical cancer (Longworth and Laimins, 2004; zur
Hausen, 2000).
All HPVs have an overall similarity in the genomic
organization: the early genes encoding viral nonstructural
proteins (E1, E2, E4, E5, E6, and E7 proteins), the late genes
encoding two capsid proteins (L1 and L2 proteins), and the
non-coding long control region (LCR) (between the L1 and E6
genes) carrying the replication origin (Fehrmann and Laimins,
2003). Most of the early genes are transcribed from the0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: ikuki@nih.go.jp (I. Kukimoto).promoter in LCR (such as HPV16 P97 and HPV31 P97), and the
E1 and late genes are transcribed from the promoter that is
located within E7 gene (such as HPV16 P670 and HPV31 P742)
(Grassmann et al., 1996; Hummel et al., 1992).
The life cycle of HPVs is closely associated with epithelial
differentiation (Longworth and Laimins, 2004). HPVs reach
and infect the basal cells of the stratified epithelia through
small epithelial lesions. In the basal cells, the viral DNA is
maintained as episomes, and the early genes are transcribed at a
very low level. When the host cells initiate terminal differen-
tiation, the HPV DNA starts to replicate and to be transcribed
efficiently. Then, HPV virions are generated in the upper layers
of the epidermis or mucosa and released from them.
Transcriptional activities of the HPV promoters are drasti-
cally changed during the terminal differentiation of the host
keratinocytes. Studies using immortalized human keratinocytes
that harbor HPV16 or HPV31 DNA have demonstrated that
HPV16 P97 or HPV31 P97 is active in undifferentiated cells,
while HPV16 P670 or HPV31 P742 is suppressed (Grassmann et
al., 1996; Hummel et al., 1992). Differentiation of the host cells
induces a massive increase in transcripts from P670 or P742,
leading to expression of the L1 and L2 capsid proteins and E1
replication protein (Klumpp and Laimins, 1999; Ozbun and6) 98 – 107
www.e
Fig. 1. Expression of FLAG-C/EBPh in HeLa cells and human foreskin
keratinocytes (HFKs). (A) Immunoblot analysis detecting endogenous and
exogenous C/EBPh. HeLa cells or HFKs were transfected with 0.4 ng of
pFLAG-C/EBPh or pFLAG-CMV2. At 48 h after the transfection, total cell
extracts were prepared and subjected to immunoblotting with antibodies against
the C-terminus of C/EBPh. FLAG-C/EBPh: FLAG-tagged full-length C/EBPh;
LAP: endogenous full-length C/EBPh; LIP: endogenous shorter isoform of
C/EBPh. (B) RT-PCR analysis of mRNA for keratin 10 and transferrin receptor.
HeLa cells were transfected with pFLAG-C/EBPh or pFLAG-CMV2. cDNA
libraries were constructed from the mRNAs extracted from the cells at 48 h after
the transfection. cDNAs for keratin 10 and transferrin receptor were amplified
by PCR with specific primers. The cDNA fragments were electrophoresed on a
1.2% agarose gel and stained with ethidium bromide.
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replication coincides with the activation of P670 or P742, it is not a
prerequisite for the activation (Bodily and Meyers, 2005; Spink
and Laimins, 2005). Cellular proteins in the differentiating
epithelium are expected to directly regulate the transcriptional
activities of the promoters, yet the molecular mechanisms of the
activation and suppression are largely unknown.
Epidermal differentiation is regulated through the action of
cellular transcription factors, which include AP-1 family
proteins (Eckert et al., 1997), POU-domain proteins (Ryan and
Rosenfeld, 1997), NF-kB family proteins (Seitz et al., 1998), and
CCAAT/enhancer binding proteins (C/EBPs) (Maytin et al.,
1999; Zhu et al., 1999). The C/EBP family of transcription
factors are known to play a role in a wide range of biological
processes, such as inflammation, the control of energy metab-
olism, and cellular proliferation and differentiation (Lekstrom-
Himes and Xanthopoulos, 1998; Ramji and Foka, 2002).
The C/EBP family is composed of six members: C/EBPa,
-h, -y, -g, -(, and -~ (Ramji and Foka, 2002). In keratinocytes,
C/EBPa, -h, -y, and -~ are expressed, and their expression
levels fluctuate during the differentiation (Maytin and Habener,
1998; Smith et al., 2004). Of particular interest is that
overexpression of C/EBPh in keratinocytes causes growth
arrest and the induction of early differentiation markers (Zhu et
al., 1999), suggesting a crucial role of C/EBPh in keratinocyte
differentiation.
The C/EBP members contain a basic leucine zipper (bZIP)
domain, which mediates the formation of homodimers or
heterodimers with other bZIP family members, at their
C-termini (Ramji and Foka, 2002). The dimers bind to the
consensus DNA sequences near the core promoters (Akira et al.,
1990). Translation of endogenous C/EBPh mRNA produces
three different products: two transactivator isoforms of 46 and
42 kDa (called as the liver-enriched transcriptional activator
proteins, LAPs) and one inhibitory isoform of 20 kDa (called as
the liver-enriched transcriptional inhibitory protein, LIP) by the
use of internal translation initiation sites (Descombes and
Schibler, 1991). The LIP consists only of the bZIP domain and
acts as a dominant negative form of C/EBPh (Descombes and
Schibler, 1991).
C/EBPh regulates cellular differentiation and proliferation
through the generation of its multiple isoforms. Changes of the
relative levels of the isoforms were observed in many cellular
processes such as liver development/regeneration (Diehl et al.,
1994), mammary grand development (Robinson et al., 1998;
Seagroves et al., 1998), and tumorigenic conversion (Raught et
al., 1996). The ectopic expression of the LIP isoform in 3T3-L1
cells disrupts terminal differentiation and induces a transfor-
mation phenotype (Calkhoven et al., 2000). The LIP isoform
expression is also upregulated in mammary epithelial cells by
the epidermal growth factor and is associated with cellular
proliferation (Baldwin et al., 2004). These findings suggest an
important role of the full-length C/EBPh in inducing cellular
differentiation.
A number of studies have demonstrated that C/EBPh affects
the transcription from the HPV promoters in LCR. C/EBPh
binds to a region of the HPV16 LCR and negatively regulatestranscription from HPV16 P97 (Kyo et al., 1993). The complex
of C/EBPh and YY1 binds to the ‘‘switch region’’ in the
HPV18 LCR and activates transcription from the promoter in
the LCR (Bauknecht et al., 1996). The downregulation of
endogenous C/EBPh results in enhancement of transcription
from the promoter in the HPV11 LCR (Wang et al., 1996).
In this study, we focused on the effect of C/EBPh on
HPV16 P97 and P670. HeLa cells and primary human foreskin
keratinocytes were transfected with plasmids expressing a
reporter (luciferase) gene driven by HPV16 P97 or P670, along
with a C/EBPh-expressing plasmid. The overexpression of
C/EBPh in the cells resulted in the activation of P670 and
repression of P97. The activation of P670 was mediated through
the direct binding of C/EBPh to two sites near the promoter.
Results
C/EBPb was expressed from the plasmid introduced in HeLa
cells and human primary foreskin keratinocytes (HFKs)
A newly constructed plasmid for FLAG-tagged C/EBPh
(FLAG-C/EBPh), pFLAG-C/EBPh, was introduced into HeLa
cells and HFKs to test its expression. The transfection caused
no significant morphological changes of the cells within 48 h.
Immunoblot analyses of the cell lysates by using anti-C/EBPh
antibody showed that full-length FLAG-C/EBPh was
expressed in the two types of cells, and revealed the presence
of two C/EBPh isoforms, LAP and LIP (Fig. 1A). The
endogenous LAP was more abundant than the endogenous
LIP in HeLa cells and LIP was not detected in HFKs. In HeLa
cells, the expression of FLAG-C/EBPh induced efficient
transcription of the keratin 10 (one of differentiation marker
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did not affect transcription of the transferrin receptor gene (Fig.
1B). The results show that exogenous C/EBPh can be
introduced in HeLa cells and HFKs, and at least the one in
the former is functional.
Transcription from HPV16 P670 was enhanced by C/EBPb
Two reporter plasmids, pGL3-P670 and pGL3-P97, in which
a firefly luciferase gene replaced the E1 and E6 genes, were
constructed to monitor the transcription from P670 and P97,
respectively (Fig. 2A). HeLa cells or HFKs were transfected
with these reporter plasmids with increasing amounts of
pFLAG-C/EBPh followed by measurement of the luciferase
activity. In HeLa cells, increasing FLAG-C/EBPh enhanced the
luciferase activity from pGL3-P670 up to 8-fold, but repressed
the activity from pGL3-P97 down to half (Fig. 2B, left panel).Fig. 2. Activation of HPV16 P670 and repression of P97 by C/EBPh. (A) Schematic
firefly luciferase gene was placed in the position of E1 gene (pGL3-P670) or E6 gene
of C/EBPh on expression of luciferase from pGL3-P670 and pGL3-P97 in HeLa cell
together with increasing amounts of pFLAG-C/EBPh (0, 0.1, 0.2, and 0.5 ng). At
Results are presented as means T standards deviations of three experiments. (C) Ef
HeLa cells were transfected with 200 ng of pGL3-P670 and 0.5 ng of pFLAG-CMV2
with deletions (FLAG-dbZIP or LIP). The structures of the C/EBPhs with deletions
were measured at 48 h after the transfection. (D) Effects of C/EBPh and hSkn-1a on
ng of pGL3-P670 and indicated amounts of pFLAG-C/EBPh and/or pHM/hSkn-1a.
pFLAG-CMV2 and pHM6 (backbone plasmid for pHM/hSkn-1a). Activation expres
and without the plasmid expressing hSkn-1a and/or the plasmid expressing C/EBPIn HFKs, C/EBPh similarly enhanced and repressed the
luciferase activities from pGL3-P670 and from pGL3-P97,
respectively (Fig. 2B, right panel). The similar effects of
C/EBPh on pGL3-P670 and pGL3-P97 were observed in HaCat
(immortalized human skin keratinocytes) and 293 (a human
fibroblast cell line) cells (data not shown). The results show
that C/EBPh enhances and represses transcription from P670
and P97, respectively, in these human cells.
The full-length FLAG-C/EBPh enhanced transcription from
P670. C/EBPh contains a transactivation domain (TAD) at its
N-terminus and a basic leucine-zipper (bZIP) type DNA-
binding domain at its C-terminus (Fig. 2C, upper panel). To
examine the effect of the LIP isoform on transcription from
P670, an expression plasmid for the FLAG-C/EBPh lacking
bZIP domain (FLAG-dbZIP) and an expression plasmid for
LIP were constructed and used to test for their abilities to
enhance transcription from P670 in HeLa cells by the transientrepresentation of the HPV16 reporter plasmids, pGL3-P670 and pGL3-P97. A
(pGL3-P97) to monitor transcription from P670 and P97, respectively. (B) Effects
s and HFKs. Cells were co-transfected with 200 ng of pGL3-P670 or pGL3-P97
48 h after the transfection, luciferase activities of cell lysates were measured.
fects of domain-deleted C/EBPhs on expression of luciferase from pGL3-P670.
(backbone plasmid), pFLAG-C/EBPh, or the expression plasmids for C/EBPhs
are schematically illustrated at the top. Luciferase activities of the cell lysates
expression of luciferase from pGL3-P670. HeLa cells were transfected with 200
The total amounts of the expression plasmids were adjusted to 20.5 ng using
sed in multiples was calculated from comparison of the luciferase activities with
h.
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tion from pGL3-P670 and only full-length FLAG-C/EBPh
enhanced transcription from pGL3-P670 (Fig. 2C, lower panel),
indicating that combined function of TAD and bZIP enhanced
the transcription from P670.
Enhancing effect by C/EBPh on the P670 transcription was
additive to that by the keratinocytes-specific transcription
factor hSkn-1a, which also enhances the transcription from
P670 as shown by our previous study (Kukimoto and Kanda,
2001). HeLa cells were transfected with pFLAG-C/EBPh,
pHM/hSkn-1a (an expression plasmid for HA-tagged hSkn-1a)
(Kukimoto and Kanda, 2001), and a mixture of pFLAG-C/
EBPh and pHM/hSkn-1a in the pGL3-P670 transient expression
assay. Expressions of FLAG-C/EBPh and HA-hSkn-1a each
enhanced luciferase activity, and the combined expression of
FLAG-C/EBPh and HA-hSkn-1a resulted in further enhance-
ment (Fig. 2D). Although the enhancement by HA-hSkn-1a
alone reached nearly maximum with 20 ng of pHM/hSkn-1a,
co-expression of C/EBPh induced further enhancement.
RT-PCR detecting hSkn-1a mRNA and Western blotting
using anti-hSkn-1a antibody did not show expression of hSkn-
1a in HeLa cells transfected with pFLAG-C/EBPh (data not
shown). HA-hSkn-1a also did not increase level of an
endogenous C/EBPh in HeLa cells (data not shown). These
results suggest that C/EBPh and hSkn-1a probably enhance the
transcription from P670 by independent molecular mechanisms.
The major cis-element(s) required for the C/EBPb-mediated
transcriptional enhancement is located in the E7 region from
nt 567 to nt 684
A series of 5V deletions were introduced into pGL3-P670 by
digestion with NdeI (pGL3-P670/dNdeI), EcoT22I (pGL3-P670/
dEcoT22I), or PvuII (pGL3-P670/dPvuII) and expressions of
the reporter gene from the deletion mutants were examined in
HeLa cells with or without FLAG-C/EBPh (Fig. 3). Being
consistent with the previous data shown by others (Bodily and
Meyers, 2005), deletion of total LCR (pGL3-P670/dNdeI)
resulted in significant reduction of luciferase activity, suggest-
ing that LCR has the enhancer function on P670. However,
C/EBPh-mediated transcriptional enhancement occurred muchFig. 3. Effects of C/EBPh on expression of luciferase from pGL3-P670 having 5V-del
and 0.5 ng of pFLAG-CMV2 or pFLAG-C/EBPh. The luciferase activities of cell
multiples was calculated from comparison of the luciferase activities with and withclearly with the reporters lacking LCR. FLAG-C/EBPh
significantly enhanced luciferase activity from pGL3-P670/
dNdeI (deletion from the 5V of LCR to nt 280) up to 16-fold
and from pGL3-P670/dEcoT22I (deletion from the 5V of LCR to
nt 566) up to 6-fold. The enhancement of transcription did not
occur from pGL3-P670/dPvuII (deletion from the 5V of LCR to
nt 684). By a yet unidentified mechanism, luciferase expression
from promoter-less plasmids, pGL3-P670/dPvuII and pGL3-
Basic, was enhanced by less than 2-fold. The data indicate that
the region between nt 567 and nt 684 contains the major
element responsible for the enhancement, although there may
be minor elements between nt 281 to nt 566.
C/EBPb bound to the upstream region of P670 in vitro
An electrophoretic mobility shift assay (EMSA) demon-
strated that a recombinant C/EBPh protein bound to at least
two sites in the HPV16 sequences from nt 501 to nt 670. An
LIP isoform fused with glutathione S-transferase (GST-LIP)
was bacterially expressed and used for the assay, since LIP
contains a minimum DNA-binding domain and shows a higher
DNA-binding affinity to its target sequence than the full-length
C/EBPh does (Descombes and Schibler, 1991). GST-LIP was
incubated with the radiolabeled DNA probes (30 bp) having
nucleotide sequences of the HPV16 genome designated A to J
(Fig. 4A), and the complex formation of GST-LIP with each
probe was detected by mobility shift. GST-LIP clearly bound to
probes E and G (Fig. 4B). Faint bindings to the other probes
seemed to be non-specific because the bindings were not
sequence-specific. A similar binding profile was observed with
a recombinant full-length C/EBPh fused with GST (data not
shown).
The probes E and G contain sequences similar to a
consensus binding motif for the C/EBP family proteins,
(N)3TTGCNNAA(N)3 (Osada et al., 1996) (Fig. 4C). The
regions from nt 580 to nt 593 (within probe E) and from nt
601 to nt 614 (within probe G) were designated as CEB#1
and CEB#2, respectively (Fig. 4A). The C/EBP consensus
motif partially resembles the binding motif for Skn-1a,
WTGCAWNN (W is A or T), and thus the previously
described hSkn-1a-binding sites Skn#2 and Skn#3 (Kuki-etion. HeLa cells were transfected with 200 ng of pGL3-P670 having 5V-deletion
lysates were measured at 48 h after the transfection. Activation expressed in
out pFLAG-C/EBPh for each deleted reporter.
Fig. 4. In vitro binding of C/EBPh with HPV16 E7 sequences. (A) The DNA probes (A to J) used in electrophoretic mobility shift assay (EMSA). Numbers in
parentheses indicate nucleotide numbers of the HPV16 DNA (Los Alamos National Library database). Nucleotide sequence from nt 501 to nt 700 in the HPV16
genome is presented. The previously identified hSkn-1a binding sites are underlined and designated as Skn#1, Skn#2, and Skn#3. Binding sequences for the C/EBP
family protein are boxed in gray and designated as CEB#1 and CEB#2. (B) EMSA detecting the complex of GST-LIP with the [32P]-labeled HPV16 probe. The
DNA–protein complex was electrophoresed on a 5% polyacrylamide gel and visualized by autoradiography. DNA probe having a consensus C/EBP binding
sequence was used as positive control for EMSA (cons). (C) Base substitutions introduced in the probes E and G. (D) Inability of GST-LIP to bind to mutated E and
G probes in EMSA. The probes E and G were mutated as shown in panel C to generate probes mE and mG, respectively, and used for EMSA with GST-LIP.
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CEB#2, respectively, on HPV16 DNA (Fig. 4A).
Nucleotide substitutions of TAGG for TTGC (Fig. 4C) were
introduced into CEB#1 and CEB#2 in the probes E and G to
produce mutated probes mE and mG, respectively. Probes mE
and mG totally lost their capabilities of complexing with GST-
LIP (Fig. 4D), indicating that the sequences of CEB#1 and
CEB#2 are essential for probes E and G, respectively, to bind
C/EBPh.
C/EBPb bound to the upstream region of P670 in vivo
Chromatin immunoprecipitation (ChIP) showed that C/
EBPh bound to the upstream region of P670 in HeLa cells.
HeLa cells transfected with pGL3-P670 together with or without
pFLAG-C/EBPh were cross-linked with formaldehyde and
lysed. The lysates were subjected to immunoprecipitation for a
DNA–protein complex using either rabbit anti-C/EBPhantibody or control rabbit IgG. After reversal of cross-links
and the proteinase K digestion of the precipitates, a DNA
fragment covering HPV16 nt 501 to nt 670 (170 bp) was
amplified by PCR and electrophoresed on an agarose-gel (Fig.
5A). The DNA fragment associated with endogenous C/EBPh
was detectable in the precipitate with anti-C/EBPh antibody
and the DNA fragment became prominent in the lysate of HeLa
cells transfected with pFLAG-C/EBPh (Fig. 5A, upper panel).
Amplification of Bcl-2 promoter sequence that does not bind to
C/EBPh (Heckman et al., 2003) from the precipitates with anti-
C/EBPh antibody was not successful (Fig. 5A, lower panel),
indicating that the amplification is specific to HPV16 P670.
Anti-FLAG antibody also precipitated the 170 bp DNA from
the lysate of HeLa cells transfected with pFLAG-C/EBPh (data
not shown).
The nucleotide substitutions in CEB#1 and CEB#2 reduced
level of DNA precipitated with anti-C/EBPh antibody. The
nucleotide substitutions that abolished bindings of GST-LIP to
Fig. 6. Effects of C/EBPh on expression of luciferase from pGL3-P670 with the
mutations in C/EBP-binding sites in HeLa cells and HFKs. HeLa cells or HFKs
were transfected with 200 ng of pGL3-mTATA/P670 (a TATA box of P97 in
pGL3-P670 was disrupted), pGL3-mTATA/P670/mSkn#1, pGL3-mTATA/P670/
mCEB#1, pGL3-mTATA/P670/mCEB#2, or pGL3-mTATA/P670/mCEB#1&2
together with 0.5 ng of pFLAG-CMV2 (bars in gray) or pFLAG-C/EBPh (bars
in black). The nucleotide substitutions introduced into the upstream region of
P670 in these plasmids are shown in Fig. 4C. At 48 h after the transfection,
luciferase activities of the cellular extracts were measured. Results are
presented as means T standards deviations of three experiments. Upper and
lower panels show data obtained by using HeLa cells and HFKs, respectively.
Fig. 5. In vivo binding of C/EBPh to P670 in HeLa cells. (A) Chromatin
immunoprecipitation analysis of complex of C/EBPh and HPV DNA. HeLa
cells transfected with pGL3-P670 together with pFLAG-CMV2 or pFLAG-C/
EBPh were cultured for 48 h and cross-linked with formaldehyde. The cells
were lysed in SDS lysis buffer and sonicated. Chromatin–C/EBPh complex
was immunoprecipitated with anti-C/EBPh antibody or normal rabbit IgG.
DNA was extracted from the precipitate and used as a template for PCR
amplification of DNA fragments of nt 501 to nt 670 (P670) and of the Bcl-2
promoter. The PCR products were electrophoresed on a 1.5% agarose gel and
stained with ethidium bromide. Data are representative of three independent
experiments. Part (0.2%) of the total input chromatin was used for PCR
analyses (input). (B) Chromatin immunoprecipitation analysis of complex of
C/EBPh and HPV DNAwith the mutations in C/EBP-binding sites. HeLa cells
were transfected with pGL3-mTATA/P670 (a TATA box of P97 in pGL3-P670
was disrupted), pGL3-mTATA/P670/mCEB#1, pGL3-mTATA/P670/mCEB#2, or
pGL3-mTATA/P670/mCEB#1&2 together with pFLAG-C/EBPh, then analyzed
by chromatin immunoprecipitation as described in panel A. The nucleotide
substitutions introduced into the upstream region of P670 in these plasmids are
shown in Fig. 4C.
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regions of pGL3-mTATA/P670, in which a TATA box of P97 in
pGL3/P670 was disrupted to reduce transcription from P97, to
produce pGL3-mTATA/P670/mCEB#1 having the mutations in
CEB#1, pGL3-mTATA/P670/mCEB#2 having the mutations in
CEB#2, and pGL3-mTATA/P670/mCEB#1&2 having the muta-
tions in both CEB#1 and CEB#2. ChIP was conducted with
lysates of HeLa cells transfected with pFLAG-C/EBPh
together with one of these plasmids (Fig. 5B). The levels of
the 170bp DNA fragments obtained from pGL3-mTATA/P670/
mCEB#1 and pGL3-mTATA/P670/mCEB#2 were lower than
that from pGL3-mTATA/P670. The level of the 170 bp DNA
obtained from pGL3-mTATA/P670/mCEB#1&2 was the lowest.These results strongly suggest that C/EBPh appears to bind to
the upstream region of P670 at CEB#1 and CEB#2 in a
sequence-specific manner in vivo.
The nucleotide substitutions in CEB#1 and CEB#2 abolished
the C/EBPb-mediated enhancement of transcription from P670
The transcription from the reporter lacking capability of
binding with C/EBPh was examined by introducing the
nucleotide substitutions into CEB#1 and CEB#2. To know the
possible contribution of P97 to the transcription from pGL3-P670,
luciferase activity from pGL3-P670 was compared with that from
pGL3-mTATA/P670 in which TATA-box of P97 in pGL3-P670
was abolished by the nucleotide substitutions as previously
described (Kukimoto and Kanda, 2001). The luciferase activity
from pGL3-P670 was slightly higher than that from pGL3-
mTATA/P670 (Fig. 6, upper panel), indicating that P97 con-
tributes to the transcription from P670 in pGL3-P670. The P97
contribution was clearer in HFKs than in HeLa cells (Fig. 6,
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CEB#1 and CEB#2, pGL3-mTATA/P670 was used as a parental
plasmid. Luciferase expressions in HeLa cells transfected with
pGL3-mTATA/P670/mCEB#1 and pGL3-mTATA/P670/
mCEB#2 were not efficiently enhanced by expression of
FLAG-C/EBPh (Fig. 6, upper panel). Luciferase expression
from pGL3-mTATA/P670/mCEB#1&2 was not enhanced. Nu-
cleotide substitutions introduced into hSkn-1a-binding site #1
(pGL3-mTATA/P670/mSkn#1) did not affect C/EBPh-mediated
enhancement. Similar results were obtained in HFKs (Fig. 6,
lower panel). The results strongly support the idea that the direct
binding of C/EBPh to CEB#1 and CEB#2 is required for the
enhancement of transcription from P670 by C/EBPh.
Discussion
Activation of the HPV late promoter occurs in host cells that
have started terminal differentiation (Longworth and Laimins,
2004). Therefore, it is reasonable to speculate that the late
promoter is activated by some of the cellular transcription
factors regulating cell differentiation. In this study, we
examined the involvement of C/EBPh, a key transcription
factor that induces the terminal differentiation of keratinocytes
(Zhu et al., 1999), in the regulation of the HPV16 promoters. It
was found that C/EBPh bound to two sites in the upstream
region of the P670 late promoter in a sequence-specific manner
and enhanced the transcription in HeLa cells and HFKs. As
reported previously (Kyo et al., 1993), C/EBPh repressed the
transcription from the P97 early promoter.
C/EBPh is known to interact with SWI/SNF chromatin
remodeling complexes and induces transcription of several
cellular genes in a chromatin environment (Kowenz-Leutz and
Leutz, 1999). A recent study of an episomal HPV31 genome
maintained in a human cervical cell line showed that a
nucleosome-free region appears in the upstream region of the
late promoter upon host cell differentiation (del Mar Pena and
Laimins, 2001). The appearance of the nucleosome-free region
strongly coincides with induction of the transcription from the
late promoter. It is possible that C/EBPh-mediated recruitment
of the SWI/SNF chromatin remodeling complex to the
upstream region of the HPV late promoter induces rearrange-
ment of the nucleosome structure around the promoter,
resulting in the appearance of a nucleosome-free region where
transcription takes place.
The sequences of CEB#1 and CEB#2 are present in the
corresponding positions in the E7 sequences of HPV31 and
HPV18, strongly suggesting that the late promoters of HPV31
and HPV18 are activated by C/EBPh. The identical sequences
are not present in the E7 sequences of HPV6, HPV11, HPV33,
and HPV58. However, substantial variations are tolerated for
C/EBP-binding sequences (Osada et al., 1996), and several
sequences containing TTGC are present in the E7 region of
these HPVs. It remains to be examined experimentally whether
C/EBPh enhances transcription from the late promoter of these
HPVs through its direct binding to the upstream region.
We have previously shown that hSkn-1a, a POU-transcrip-
tion factor inducing keratinocyte differentiation, binds toSkn#1 and Skn#2 (Fig. 4A) and activates HPV16 P670 by
displacement of YY1 repressor (Kukimoto and Kanda, 2001).
hSkn-1a does not bind to the region previously designated as
Skn#3. When both C/EBPh and hSkn-1a were expressed in
HeLa cells, the enhancement of transcription from P670 seemed
to be additive (Fig. 2D). Probably hSkn-1a binds to Skn#1 and
C/EBPh binds to CEB#2 (Fig. 4A). Since CEB#1 and Skn#2
partially overlap (Figs. 4A and C), it is not clear which of C/
EBPh and hSkn-1a binds to the site dominantly. Our real-time
RT-PCR analysis of differentiating primary keratinocytes
showed that induction of hSkn-1a preceded induction of C/
EBPh during differentiation (T. Takeuchi et al., unpublished
data). It is therefore possible that hSkn-1a first binds to Skn#2
and relieves the YY1-mediated repression, and then hSkn-1a is
displaced by C/EBPh.
C/EBPh repressed transcription from HPV16 P97 as
described previously (Kyo et al., 1993). C/EBPh disrupts the
binding of TATA-binding protein to the TATA box in the early
promoter of HPV18 (Bauknecht and Shi, 1998). It is possible
that the reduction of E6 and E7, which are produced from
transcripts from P97 and have function to delay the terminal
differentiation, is required for the later stage of the differen-
tiation-associated viral propagation.
This study has shown that C/EBPh enhances the transcrip-
tion from the HPV16 late promoter. In the epidermis, C/EBPh
is expressed at a low level in the basal cell layers where the
HPV late genes are not transcribed and at a high level in the
middle and upper stratum spinosum where the HPV late genes
are actively transcribed. It is very likely that C/EBPh is
involved in the differentiation-associated life cycle of HPV16.
Materials and methods
Construction of plasmids
The cDNA of C/EBPh was provided by DNA Bank,
BioRecource Center, RIKEN (Ibaraki, Japan), and was inserted
in flame between EcoRI and SalI sites of pFLAG-CMV2
(Sigma-Aldrich, St. Louis, MO) to generate an expression
plasmid for an N-terminal FLAG-tagged C/EBPh, pFLAG-C/
EBPh. The expression plasmid for C/EBPh with deletion of the
DNA-binding domain was constructed by digestion of pFLAG-
C/EBPh with SacI and self-ligation. The DNA fragment
encoding an LIP isoform of C/EBPh was synthesized by
PCR using pFLAG-C/EBPh as a template with primers
(forward, 5V-CGA ATT CGC CAT GGC GGC GGG CTT
CCC GTA-3V; reverse, 5V-GCG TCG ACT CTA GCA GTG
GCC GGA-3V; restriction digestion sites were underlined), and
was inserted into pCMV5 (a kind gift from Dr. Michael
Megner) as a EcoRI–SalI fragment to generate an expression
plasmid for LIP. The bacterial expression plasmid for an LIP
fused with glutathione S-transferase (GST-LIP) was made by
insertion of the EcoRI–SalI fragment of LIP into pGEX-6P-1
(Amersham Biosciences, Piscataway, NJ).
To construct the P670 reporter plasmid, a PstI–NcoI
fragment of HPV16 (from nt 7003 to 7904 and from nt 1 to
868) was inserted between SmaI and NcoI sites of pGL3-Basic
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the HPV16 DNAwas fused with the luciferase DNA at the first
ATG codon of the HPV16 E1 gene. To construct the P97
reporter plasmid pGL3-P97, a DNA fragment of HPV16 (from
nt 7003 to 7904 and from nt 1 to 101) was synthesized by PCR
using primers (forward, 5V-CCC AAG CTT CTG CAG ACC
TAG ATC AGT-3V; reverse, 5V-CAT GCC ATG GCA GTT
CTC TTT TGG TGC ATA A-3V; restriction digestion sites were
underlined), and was inserted between HindIII and NcoI sites
of pGL3-Basic. Deleted P670 reporter plasmids, pGL3-P670/
dNdeI, pGL3-P670/dEcoT22I, and pGL3-P670/dPvuII, were
made by digestion of pGL3-P670 with SacI and NdeI, with
SacI and EcoT22I, and with SacI and PvuII, respectively,
followed by blunting and self-ligation. All nucleotide substitu-
tions in the reporter constructs were introduced using a Mutan-
Super Express Km site-directed mutagenesis kit (Takara,
Osaka, Japan) or standard PCR techniques based on KOD-
plus polymerase (TOYOBO, Osaka, Japan). All mutations
were verified by sequencing.
Cell culture and luciferase assay
HeLa cells were grown in Dulbecco’s modified Eagle
medium supplemented with 10% fetal bovine serum in 5%
CO2 at 37 -C. Primary human foreskin keratinocytes (HFKs)
were purchased from Kurabo (Osaka, Japan), and grown in
serum-free keratinocyte growth medium (Kurabo) in 5% CO2
at 37 -C. For luciferase assays, 3  104 HeLa cells or 4  104
HFKs were seeded onto 24-well plates. HeLa cells and HFKs
were cultured for 4 h and overnight, respectively, before
transfection. The cells were transfected with 200 ng of
luciferase reporter plasmids and 0.1–0.5 ng of pFLAG-C/
EBPh by using FuGENE-6 reagent (Roche Applied Science,
Indianapolis, IN). To monitor transfection efficiency, the cells
were co-transfected with 5 ng of the cytomegalovirus
promoter-driven Renilla-luciferase plasmid. Firefly and Renilla
luciferase activities were measured at 48 h after transfection by
using the Dual-Glo luciferase assay kit (Promega) and a
TopCount microplate luminometer (Perkin-Elmer Sciences Inc,
Boston, MA). Firefly luciferase activities were normalized
using Renilla-luciferase activities. Each experiment was done
in triplicate and repeated at least three times.
Western blot analysis
Total extracts of 1.2  105 HeLa cells or 1.6  105 HFKs
transfected with 0.4 ng of pFLAG-C/EBPh or pFLAG-CMV2
were electrophoresed on a 12% SDS-Polyacrylamide gel. After
transfer of proteins to a nitrocellulose membrane (Schleicher and
Schuell, Dassel, Germany), the membrane was blocked with 5%
skim milk in PBS-0.1% Tween 20 at room temperature and then
incubated with rabbit anti-C/EBPh antibody (C-19) (Santa Cruz
Biotechnology, Santa Cruz, CA) for 1 h. The membranes were
washed and incubated with peroxidase-conjugated goat anti-
rabbit antibody for 1 h. Peroxidase activity was detected with the
enhanced chemiluminescence detection method (ECL plus kit,
Amersham Biosciences).Electrophoretic mobility shift assay
The GST-LIP fusion protein was expressed in Escherichia
coli strain JM109 and purified by GSTrap affinity-column
chromatography (Amersham Biosciences) with AKTAprime
(Amersham Biosciences). A mixture of double-stranded [32P]-
labeled oligonucleotides (0.4 pmol), 1 Ag of GST-LIP, and 1 Ag
of poly (dI/dC) in a final volume of 10 Al of binding buffer (20
mM Tris–HCl, pH 8.0, 50 mM NaCl, 10 mM MgCl2, 10%
glycerol, 1 mM DTT, and 40 Ag/ml BSA) was incubated at
room temperature for 30 min. Then, the samples were loaded
on a 5% polyacrylamide gel and electrophoresed in 0.5 Tris–
borate/EDTA buffer at room temperature. The gels were dried
and visualized by autoradiography on X-ray films. The sense
sequences of double-stranded oligonucleotides are as follows:
A (501–530), 5V-CCG GTC GAT GTA TGT CTT GTT GCA
GAT CAT-3V; B (531–560), 5V-CAA GAA CAC GTA GAG
AAA CCC AGC TGT AAT-3V; C (551–580), 5V-CAG CTG
TAA TCA TGC ATG GAG ATA CAC CTA-3V; D (561–590),
5V-CAT GCATGG AGATAC ACC TAC ATT GCATGA-3V; E
(571–600), 5V-GATACA CCTACATTG CAT GAATATATG
TTA-3V; F (581–610), 5V-CAT TGC ATG AATATATGT TAG
ATT TGC AAC-3V; G (591–620), 5V-ATATAT GTTAGATTT
GCA ACC AGA GAC AAC-3V; H (611–640), 5V-CAG AGA
CAA CTG ATC TCT ACT GTT ATG AGC-3V; I (631–660),
5V-TGT TAT GAG CAA TTA AAT GAC AGC TCA GAG; J
(641–670), 5V-AAT TAA ATG ACA GCT CAG AGG AGG
AGG ATG-3V; mE, 5V-GAT ACA CCT ACA TAG GAC GAA
TAT ATG TTA-3V; mG, 5V-ATA TAT GTT AGA TTA GGA
CCC AGA GAC AAC-3V; C/EBP-cons, 5V-AAG CTG CAG
ATT GCG CAATCT GCA GCT T-3V. Numbers in parentheses
indicate nucleotide numbers of the HPV16 genome (the HPV
Sequence Database of Los Alamos National Laboratory) and
nucleotides used for substitution mutations are underlined.
Chromatin immunoprecipitation
HeLa cells (8  105 cells) were grown on a 100-mm dish for
4 h and then transfected with 6 Ag of the reporter construct and
6 ng of pFLAG-C/EBPh or pFLAG-CMV2 using FuGENE-6.
At 48 h after the transfection, the cells were cross-linked with
1% formaldehyde for 5 min at 37 -C followed by a 5-min
treatment with 125 mM glycine to quench cross-linking. The
cross-linked cells were lysed in 200 Al of lysis buffer (1% SDS,
10 mM EDTA, 50 mM Tris–HCl, pH 8.0) supplemented with
protease inhibitor mixture (Roche Applied Science), incubated
on ice for 10 min, and sonicated using a Bioruptor (Cosmobio,
Tokyo, Japan). The sonication resulted in an average DNA
fragment size of 500 bp. One hundred microliters of the
sonicated materials was diluted with 900 Al of ChIP dilution
buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167
mM NaCl, 16.7 mM Tris–HCl, pH 8.0) and precleared with
salmon sperm DNA/protein G-agarose beads. Part (2%) of the
precleared lysate was taken as input chromatin for PCR
analyses. The supernatant was incubated overnight at 4 -C
with anti-C/EBPh (Santa Cruz) or normal rabbit IgG. The
chromatin–antibody complex was collected through incuba-
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The beads were washed sequentially for 5 min at 4 -C in wash
buffer I (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM
NaCl, Tris–HCl, pH 8.0), wash buffer II (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 500 mM NaCl, Tris–HCl, pH
8.0), wash buffer III (0.25 M LiCl, 1% NP-40, 1% sodium
deoxycholate, 1 mM EDTA, 10 mM Tris–HCl, pH 8.0), and
TE (10 mM Tris–HCl, pH 8.0, 1 mM EDTA) twice, then
extracted with 200 Al of elution buffer (1% SDS, 0.1 M
NaHCO3, 10 mM DTT). The eluted chromatin and the input
chromatin were heated at 65 -C for 4 h to reverse the cross-
links, followed by proteinase K digestion overnight at 37 -C.
DNA was recovered by phenol/chloroform extraction and
ethanol precipitation. The purified DNA fragments were used
as templates for PCR amplification to detect the protein
occupancy of the HPV P670. PCR primers were as follows:
forward, 5V-CCG GTC GAT GTA TGT CTT GTT GCA GAT
CAT-3V; reverse, 5V-CAT CCT CCT CCT CTG AGC TGT CAT
TTA ATT-3V. These primers amplify 170 bp DNA from nt 501
to nt 670 of the HPV16 sequence. PCR consisted of one cycle
of initial denaturation at 94 -C for 1 min and 21 cycles of the
following conditions: denaturation at 94 -C for 20 s, annealing
at 55 -C for 30 s, and extension at 72 -C for 1 min. Human Bcl-
2 promoter sequence (from 748 to 587) (Heckman et al.,
2003) was amplified as a negative control for ChIP analysis.
PCR products were separated by 1.5% agarose gel electropho-
resis and visualized with ethidium bromide.
Acknowledgments
We thank Dr. Michael Wegner for providing us the
pCMV5 plasmid and Dr. Kunito Yoshiike for critical reading
of the manuscript. This work was supported by a grant-in-aid
from the Ministry of Health, Labor, and Welfare for the
Third-Term Comprehensive Control Research for Cancer (to
T. K.), and a grant-in-aid for Young Scientists (B) from the
Ministry of Education, Culture, Sports, Science, and Tech-
nology (to I. K.).
References
Akira, S., Isshiki, H., Sugita, T., Tanabe, O., Kinoshita, S., Nishio, Y.,
Nakajima, T., Hirano, T., Kishimoto, T., 1990. A nuclear factor for IL-6
expression (NF-IL6) is a member of a C/EBP family. EMBO J. 9 (6),
1897–1906.
Baldwin, B.R., Timchenko, N.A., Zahnow, C.A., 2004. Epidermal growth
factor receptor stimulation activates the RNA binding protein CUG-BP1
and increases expression of C/EBPbeta-LIP in mammary epithelial cells.
Mol. Cell. Biol. 24 (9), 3682–3691.
Bauknecht, T., Shi, Y., 1998. Overexpression of C/EBPbeta represses human
papillomavirus type 18 upstream regulatory region activity in HeLa cells by
interfering with the binding of TATA-binding protein. J. Virol. 72 (3),
2113–2124.
Bauknecht, T., See, R.H., Shi, Y., 1996. A novel C/EBP beta–YY1 complex
controls the cell-type-specific activity of the human papillomavirus type 18
upstream regulatory region. J. Virol. 70 (11), 7695–7705.
Bodily, J.M., Meyers, C., 2005. Genetic analysis of the human papilloma-
virus type 31 differentiation-dependent late promoter. J. Virol. 79 (6),
3309–3321.
Calkhoven, C.F., Muller, C., Leutz, A., 2000. Translational control ofC/EBPalpha and C/EBPbeta isoform expression. Genes Dev. 14 (15),
1920–1932.
del Mar Pena, L.M., Laimins, L.A., 2001. Differentiation-dependent chromatin
rearrangement coincides with activation of human papillomavirus type 31
late gene expression. J. Virol. 75 (20), 10005–10013.
Descombes, P., Schibler, U., 1991. A liver-enriched transcriptional activator
protein, LAP, and a transcriptional inhibitory protein, LIP, are translated
from the same mRNA. Cell 67 (3), 569–579.
Diehl, A.M., Michaelson, P., Yang, S.Q., 1994. Selective induction of
CCAAT/enhancer binding protein isoforms occurs during rat liver devel-
opment. Gastroenterology 106 (6), 1625–1637.
Eckert, R.L., Crish, J.F., Robinson, N.A., 1997. The epidermal keratinocyte as a
model for the study of gene regulation and cell differentiation. Physiol. Rev.
77 (2), 397–424.
Fehrmann, F., Laimins, L.A., 2003. Human papillomaviruses: targeting
differentiating epithelial cells for malignant transformation. Oncogene 22
(33), 5201–5207.
Grassmann, K., Rapp, B., Maschek, H., Petry, K.U., Iftner, T., 1996.
Identification of a differentiation-inducible promoter in the E7 open reading
frame of human papillomavirus type 16 (HPV-16) in raft cultures of a new
cell line containing high copy numbers of episomal HPV-16 DNA. J. Virol.
70 (4), 2339–2349.
Heckman, C.A., Wheeler, M.A., Boxer, L.M., 2003. Regulation of Bcl-2
expression by C/EBP in t(14;18) lymphoma cells. Oncogene 22 (39),
7891–7899.
Hummel, M., Hudson, J.B., Laimins, L.A., 1992. Differentiation-induced and
constitutive transcription of human papillomavirus type 31b in cell lines
containing viral episomes. J. Virol. 66 (10), 6070–6080.
Klumpp, D.J., Laimins, L.A., 1999. Differentiation-induced changes in
promoter usage for transcripts encoding the human papillomavirus type
31 replication protein E1. Virology 257 (1), 239–246.
Kowenz-Leutz, E., Leutz, A., 1999. A C/EBP beta isoform recruits the
SWI/SNF complex to activate myeloid genes. Mol. Cell 4 (5), 735–743.
Kukimoto, I., Kanda, T., 2001. Displacement of YY1 by differentiation-specific
transcription factor hSkn-1a activates the P(670) promoter of human
papillomavirus type 16. J. Virol. 75 (19), 9302–9311.
Kyo, S., Inoue, M., Nishio, Y., Nakanishi, K., Akira, S., Inoue, H., Yutsudo, M.,
Tanizawa, O., Hakura, A., 1993. NF-IL6 represses early gene expression of
human papillomavirus type 16 through binding to the noncoding region.
J. Virol. 67 (2), 1058–1066.
Lekstrom-Himes, J., Xanthopoulos, K.G., 1998. Biological role of the
CCAAT/enhancer-binding protein family of transcription factors. J. Biol.
Chem. 273 (44), 28545–28848.
Longworth, M.S., Laimins, L.A., 2004. Pathogenesis of human papilloma-
viruses in differentiating epithelia. Microbiol. Mol. Biol. Rev. 68 (2),
362–372.
Maytin, E.V., Habener, J.F., 1998. Transcription factors C/EBP alpha, C/EBP
beta, and CHOP (Gadd153) expressed during the differentiation program of
keratinocytes in vitro and in vivo. J. Invest. Dermatol. 110 (3), 238–246.
Maytin, E.V., Lin, J.C., Krishnamurthy, R., Batchvarova, N., Ron, D., Mitchell,
P.J., Habener, J.F., 1999. Keratin 10 gene expression during differentiation
of mouse epidermis requires transcription factors C/EBP and AP-2. Dev.
Biol. 216 (1), 164–181.
Osada, S., Yamamoto, H., Nishihara, T., Imagawa, M., 1996. DNA binding
specificity of the CCAAT/enhancer-binding protein transcription factor
family. J. Biol. Chem. 271 (7), 3891–3896.
Ozbun, M.A., Meyers, C., 1997. Characterization of late gene transcripts
expressed during vegetative replication of human papillomavirus type 31b.
J. Virol. 71 (7), 5161–5172.
Ramji, D.P., Foka, P., 2002. CCAAT/enhancer-binding proteins: structure,
function and regulation. Biochem. J. 365 (Pt. 3), 561–575.
Raught, B., Gingras, A.C., James, A., Medina, D., Sonenberg, N., Rosen,
J.M., 1996. Expression of a translationally regulated, dominant-negative
CCAAT/enhancer-binding protein beta isoform and up-regulation of the
eukaryotic translation initiation factor 2alpha are correlated with
neoplastic transformation of mammary epithelial cells. Cancer Res. 56
(19), 4382–4386.
Robinson, G.W., Johnson, P.F., Hennighausen, L., Sterneck, E., 1998. The
I. Kukimoto et al. / Virology 346 (2006) 98–107 107C/EBPbeta transcription factor regulates epithelial cell proliferation and
differentiation in the mammary gland. Genes Dev. 12 (12), 1907–1916.
Ruesch, M.N., Stubenrauch, F., Laimins, L.A., 1998. Activation of papilloma-
virus late gene transcription and genome amplification upon differentiation
in semisolid medium is coincident with expression of involucrin and
transglutaminase but not keratin-10. J. Virol. 72 (6), 5016–5024.
Ryan, A.K., Rosenfeld, M.G., 1997. POU domain family values: flexi-
bility, partnerships, and developmental codes. Genes Dev. 11 (10),
1207–1225.
Seagroves, T.N., Krnacik, S., Raught, B., Gay, J., Burgess-Beusse, B.,
Darlington, G.J., Rosen, J.M., 1998. C/EBPbeta, but not C/EBPalpha, is
essential for ductal morphogenesis, lobuloalveolar proliferation, and
functional differentiation in the mouse mammary gland. Genes Dev. 12
(12), 1917–1928.
Seitz, C.S., Lin, Q., Deng, H., Khavari, P.A., 1998. Alterations in NF-kappaB
function in transgenic epithelial tissue demonstrate a growth inhibitory role
for NF-kappaB. Proc. Natl. Acad. Sci. U.S.A. 95 (5), 2307–2312.
Smith, C., Zhu, K., Merritt, A., Picton, R., Youngs, D., Garrod, D., Chidgey,M., 2004. Regulation of desmocollin gene expression in the epidermis:
CCAAT/enhancer-binding proteins modulate early and late events in
keratinocyte differentiation. Biochem. J. 380 (Pt. 3), 757–765.
Spink, K.M., Laimins, L.A., 2005. Induction of the human papillomavirus type
31 late promoter requires differentiation but not DNA amplification.
J. Virol. 79 (8), 4918–4926.
Wang, H., Liu, K., Yuan, F., Berdichevsky, L., Taichman, L.B., Auborn, K.,
1996. C/EBPbeta is a negative regulator of human papillomavirus type 11
in keratinocytes. J. Virol. 70 (7), 4839–4844.
Zhu, S., Oh, H.S., Shim, M., Sterneck, E., Johnson, P.F., Smart, R.C., 1999.
C/EBPbeta modulates the early events of keratinocyte differentiation
involving growth arrest and keratin 1 and keratin 10 expression. Mol. Cell.
Biol. 19 (10), 7181–7190.
zur Hausen, H., 1996. Papillomavirus infections—A major cause of human
cancers. Biochim. Biophys. Acta 1288 (2), F55–F78.
zur Hausen, H., 2000. Papillomaviruses causing cancer: evasion from host–
cell control in early events in carcinogenesis. J. Natl. Cancer Inst. 92 (9),
690–698.
